Page last updated: 2024-08-02 14:55:27
ly 379268
Description
LY 379268: group II metabotropic glutamate receptor agonist; structure in first source [MeSH]
LY 379268 : An organic heterobicyclic compound that is (1R,5S)-2-oxabicyclo[3.1.0]hexane carrying amino, carboxy, and carboxy groups at positions 4R, 4R and 6R, respectively. It is a potent agonist of group II metabotropic glutamate receptors mGluR2 and mGluR3 (EC50 = 2.69 nM and 4.48 nM, respectively) that exhibits antipsychotic-like action in animal models of schizophrenia. [CHeBI]
Cross-References
Synonyms (33)
| Synonym |
|---|
| (1r,4r,5s,6r)-4-amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid |
| 4-amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid |
| bdbm50074749 |
| (1s,2r,5r,6r)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid |
| gtpl1394 |
| NCGC00159572-01 |
| ly-379268 , |
| CHEMBL275079 , |
| 191471-52-0 |
| ly-379,268 |
| ly379268 |
| ly 379268 |
| (1r,4r,5s,6r)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid |
| CHEBI:192545 |
| AKOS006306876 |
| SCHEMBL2454646 |
| DTXSID90436637 |
| J-012378 |
| 191471-50-8 |
| Q6460430 |
| 2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid, 4-amino-, (1r,4r,5s,6r)- |
| MS-23010 |
| 2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylicacid,4-amino-,(1r,4r,5s,6r)-rel- |
| HY-103558 |
| EX-A6709 |
| CS-0028092 |
| 2-oxabicyclo(3.1.0)hexane-4,6-dicarboxylic acid, 4-amino-, (1r-(1.alpha.,4.beta.,5.alpha.,6.alpha.))- |
| (1r,4r,5s,6r)-4-amino-2-oxabicyclo(3.1.0)hexane-4,6-dicarboxylic acid |
| 2-oxabicyclo(3.1.0)hexane-4,6-dicarboxylic acid, 4-amino-, (1r,4r,5s,6r)- |
| s96jf4j697 , |
| 2-oxabicyclo(3.1.0)hexane-4,6-dicarboxylic acid, 4-amino-, (1r-(1alpha,4beta,5alpha,6alpha))- |
| (-)-ly-379268 |
| unii-s96jf4j697 |
Roles (4)
| Role | Description |
|---|
| metabotropic glutamate receptor agonist | An agonist that selectively binds to and activates a metabotropic glutamate receptor. |
| neuroprotective agent | Any compound that can be used for the treatment of neurodegenerative disorders. |
| antipsychotic agent | Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. |
| anxiolytic drug | Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. |
Drug Classes (3)
Protein Targets (17)
Inhibition Measurements
Activation Measurements
Other Measurements
Bioassays (62)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID221694 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human mGluR7 | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID275489 | Agonist activity at human mGluR2 assessed as effect on cAMP production in RGT cells | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID107091 | Inhibition of c-AMP by human Metabotropic glutamate receptor 6 (mGluR6) expressed in non-neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID107059 | Agonist potency against cloned metabotropic glutamate receptor 5 | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID118122 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 100 mg/kg dose 1 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID118128 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 30 mg/kg dose 1 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID118127 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 3 mg/kg dose 2 hr after systemic administration. | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID275487 | Displacement of [3H]LY341495 from human recombinant mGluR2 in RGT cells | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID109163 | Ability to displace [3H]LY-341,495 from recombinant human Metabotropic glutamate receptor 3 expressed in RGT cells. | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID143153 | Ability to displace [3H]CGP-39653 binding to N-methyl-D-aspartate glutamate receptor from rat forebrain | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID108829 | Ability to displace [3H]LY-341,495 from recombinant human Metabotropic glutamate receptor 2 subtypes expressed in RGT cells. | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID221690 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human mGluR6 | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID275499 | Antagonist activity against human mGluR7a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID109149 | Inhibition of c-AMP by human Metabotropic glutamate receptor 3 (mGluR3) expressed in non-neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID75022 | Ability to displace [3H]LY-341,495 binding to Group II Metabotropic glutamate receptor from rat forebrain | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID93553 | Ability to displace [3H]-KA binding to Ionotropic glutamate receptor kainate from rat forebrain | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID275496 | Antagonist activity against human mGluR1a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID275498 | Antagonist activity against human mGluR4a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID275495 | Agonist activity at human mGluR7a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID118124 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 100 mg/kg dose 4 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID118126 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 3 mg/kg dose 2 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID109491 | Phosphoinositide hydrolysis by human Metabotropic glutamate receptor 5 (mGluR5) expressed in non neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID275497 | Antagonist activity against human mGluR5a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID107269 | Inhibition of c-AMP by human Metabotropic glutamate receptor 8 (mGluR8) expressed in non-neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID109153 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human Metabotropic glutamate receptor 3 | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID108489 | Agonist potency against cloned human metabotropic glutamate receptor 1 | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID275494 | Agonist activity at human mGluR4a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID113827 | Effect on limbic seizures induced by ACPD in NIH Swiss mice 4 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID705392 | Agonist activity at human mGLUR3 assessed as inhibition of forskolin-stimulated cAMP production by cell-based assay | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
ISSN: 1464-3405 | Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo. |
| AID107261 | Agonist potency against cloned Metabotropic glutamate receptor 7 (mGluR-7). | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID221685 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human mGluR5a | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID275490 | Agonist activity at human mGluR3 assessed as effect on cAMP production in RGT cells | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID108830 | Agonist potency against cloned Metabotropic glutamate receptor 2 (mGluR-2). | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID118130 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 30 mg/kg dose 4 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID221675 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human mGluR4a | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID275491 | Agonist activity at human mGluR8 assessed as effect on cAMP production in RGT cells | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID108680 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human Metabotropic glutamate receptor 2 | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID118121 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 10 mg/kg dose 4 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID221697 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human mGluR8 | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID118120 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 10 mg/kg dose 1 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID108354 | Phosphoinositide hydrolysis by human Metabotropic glutamate receptor 1 (mGluR1) expressed in non-neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID705393 | Agonist activity at human mGLUR2 assessed as inhibition of forskolin-stimulated cAMP production by cell-based assay | 2012 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
ISSN: 1464-3405 | Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo. |
| AID275488 | Displacement of [3H]LY341495 from human recombinant mGluR3 in RGT cells | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID109341 | Agonist potency against cloned human Metabotropic glutamate receptor 4 (mGluR-4) | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID92201 | Ability to displace [3H]AMPA binding to Ionotropic glutamate receptor AMPA from rat forebrain | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID275493 | Agonist activity at human mGluR5a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID107274 | Agonist potency against cloned Metabotropic glutamate receptor 8 (mGluR-8). | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID275492 | Agonist activity at human mGluR1a assessed as effect on cAMP production in RGT cells upto 100 uM | 2007 | Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
ISSN: 0022-2623 | Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. |
| AID109323 | Inhibition of c-AMP by human Metabotropic glutamate receptor 4 (mGluR4) expressed in non-neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID113825 | Effect on limbic seizures induced by ACPD in NIH Swiss mice 1 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID118129 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 30 mg/kg dose 2 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID109164 | Agonist potency against cloned Metabotropic glutamate receptor 3 (mGluR-3). | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID107256 | Inhibition of c-AMP by human Metabotropic glutamate receptor 7 (mGluR7) expressed in non-neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID113826 | Effect on limbic seizures induced by ACPD in NIH Swiss mice 2 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID118123 | Effect on limbic seizures induced by ACPD in NIH Swiss mice at 100 mg/kg dose 2 hr after systemic administration | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID107093 | Agonist potency against cloned Metabotropic glutamate receptor 6 (mGluR-6). | 2000 | Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
ISSN: 0022-2623 | Ligands for glutamate receptors: design and therapeutic prospects. |
| AID108669 | Inhibition of c-AMP by human Metabotropic glutamate receptor 2 (mGluR2) expressed in non-neuronal cells | 2002 | Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
ISSN: 0022-2623 | (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. |
| AID221515 | Inhibition of forskolin stimulated cAMP production in RGT cells expressing recombinant human mGluR1a | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346272 | Human mGlu6 receptor (Metabotropic glutamate receptors) | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
| AID1346271 | Human mGlu2 receptor (Metabotropic glutamate receptors) | 1999 | Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
ISSN: 0022-2623 | Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists f |
Research
Studies (221)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (2.71) | 18.2507 |
| 2000's | 85 (38.46) | 29.6817 |
| 2010's | 114 (51.58) | 24.3611 |
| 2020's | 16 (7.24) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (1.36%) | 6.00% |
| Case Studies | 1 (0.45%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 217 (98.19%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| pilsicainide | | organic heterobicyclic compound;
secondary carboxamide | anti-arrhythmia drug;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pentylenetetrazole | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ascaridole | | organic heterobicyclic compound;
organic peroxide;
p-menthane monoterpenoid | antileishmanial agent;
antinematodal drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,2-benzisothiazoline-3-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | disinfectant;
drug allergen;
environmental contaminant;
platelet aggregation inhibitor;
sensitiser;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5,6,7-tetrachlorophthalide | | gamma-lactone;
organic heterobicyclic compound;
propan-1-ol;
tetrachlorobenzene | antifungal agrochemical;
melanin synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perindoprilat | | dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| u 69593 | | monocarboxylic acid amide;
N-alkylpyrrolidine;
organic heterobicyclic compound;
oxaspiro compound | anti-inflammatory agent;
diuretic;
kappa-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| verruculotoxin | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,6,7,8-tetrahydrocyclopenta[2,3]thieno[2,4-d]pyrimidin-1-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-oxo-2-benzothiopyran-3-carboxylic acid methyl ester | | organic heterobicyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| luciduline | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[2-[(4-fluorophenyl)methylamino]-2-oxoethyl]-2-methyl-5-thieno[3,2-b]pyrrolecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cyclohexyl-N,4-dimethyl-5-thieno[3,2-b]pyrrolecarboxamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-5-thieno[3,2-b]pyrrolecarboxylic acid [1-oxo-1-(2-phenylethylamino)propan-2-yl] ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(5,6-dimethyl-4-oxo-3H-thieno[2,3-d]pyrimidin-2-yl)thio]-N-(4-methyl-2-thiazolyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-4-[2-oxo-2-(2-phenylethylamino)ethyl]-5-thieno[3,2-b]pyrrolecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,6-dimethyl-5,8-dihydropyrano[4,5]thieno[1,2-c]pyrimidin-4-amine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-ethyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)thio]-N-(2-furanylmethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(5,6-dimethyl-4-oxo-3-phenyl-2-thieno[2,3-d]pyrimidinyl)thio]-N-(2-furanylmethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-[(2-fluorophenyl)methyl]-2,4-dimethyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-5-thieno[3,2-b]pyrrolecarboxylic acid [2-oxo-2-(thiophen-2-ylmethylamino)ethyl] ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[5-(4-methylphenyl)-3-thiazolo[2,3-c][1,2,4]triazolyl]thio]-N-(6-methyl-2-pyridinyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-amino-5-(4-ethoxy-3-methoxyphenyl)-4-oxo-3,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
oxacycle | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-ethyl-6-methyl-5,8-dihydro-1H-thiopyrano[2,3]thieno[2,4-b]pyrimidine-2,4-dione | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(7-methyl-4-oxo-3-phenyl-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]acetic acid methyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-19776 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[2-(dimethylamino)ethylthio]-6,6-dimethyl-5,8-dihydropyrano[4,5]thieno[1,2-c]pyrimidin-4-amine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[6,6-dimethyl-2-(propan-2-ylthio)-5,8-dihydropyrano[2,3]thieno[2,4-b]pyrimidin-4-yl]thio]-N-(2-furanylmethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(4-fluorophenyl)methyl]-3-(2-furanylmethyl)-4-imino-6,6-dimethyl-5,8-dihydropyrano[2,3]thieno[2,4-b]pyrimidin-2-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-chlorophenyl)-2-[3-(2-furanylmethyl)-4-imino-6,6-dimethyl-2-oxo-5,8-dihydropyrano[2,3]thieno[2,4-b]pyrimidin-1-yl]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[[2-(3,5-dimethyl-1-pyrazolyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl]amino]-1-propanol | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(3,5-dimethyl-1-pyrazolyl)-6,6-dimethyl-5,8-dihydropyrano[2,3]thieno[2,4-b]pyrimidin-4-yl]thio]-N-(2-thiazolyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[3-(2-furanylmethyl)-4-imino-6,6-dimethyl-2-oxo-5,8-dihydropyrano[2,3]thieno[2,4-b]pyrimidin-1-yl]-N-phenylacetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1-benzotriazolyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-furanyl)-5,6,7,8-tetrahydro-3H-[1]benzothiolo[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(4-chlorophenyl)-3H-thieno[2,3-d]pyrimidine-4-thione | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-furanylmethyl)-3-methyl-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-amine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-5-(5-methyl-2-furanyl)-3-(1-pyrrolyl)-4-thieno[2,3-d]pyrimidinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methyl-6-phenyl-3H-thieno[2,3-d]pyrimidine-4-thione | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-ethyl-5-methyl-4-oxo-6-thieno[2,3-d]pyrimidinecarboxylic acid | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-dimethyl-4-[[(5-phenyl-3-thiazolo[2,3-c][1,2,4]triazolyl)thio]methyl]isoxazole | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,6-dimethyl-N-(3-pyridinylmethyl)-4-thieno[2,3-d]pyrimidinamine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-prop-2-enyl-2-sulfanylidene-5,6,7,8-tetrahydro-1H-[1]benzothiolo[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-sulfanylidene-1,6,7,8,9,10-hexahydropyrimido[3,4]pyrrolo[3,5-a]azepine-11-carbonitrile | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-amino-2-(4-methylphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3,5-dimethyl-4-isoxazolyl)methylthio]-3-prop-2-enyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-methoxyphenyl)-6-phenyl-4-thieno[2,3-d]pyrimidinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-furanylmethyl)-2-(4-oxo-6-phenyl-3-thieno[2,3-d]pyrimidinyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(5,6-dimethyl-1-benzimidazolyl)-5-phenylthieno[2,3-d]pyrimidine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-(dimethylamino)-3-(4-methoxyphenyl)-4-pyrido[1,2]thieno[3,4-d]pyrimidinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[2,4-dioxo-3-(2-phenylethyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-1-yl]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3,5-dimethyl-4-isoxazolyl)methylthio]-3-prop-2-enyl-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1,3-benzodioxol-5-ylmethylthio)-5-(2-furanyl)-3-prop-2-enyl-4-thieno[2,3-d]pyrimidinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-24412 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-17286 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [5,6-dimethyl-3-(pyridin-4-ylmethyl)-2,4-dihydrothieno[2,3-d]pyrimidin-1-yl]-(2-furanyl)methanone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1-benzimidazolyl)-5-(4-methylphenyl)thieno[2,3-d]pyrimidine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-hydroxypropyl)-4-[(1-oxo-2,6,7,8-tetrahydrocyclopenta[2,3]thieno[2,4-b]pyrimidin-3-yl)thio]butanamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,6-dimethyl-2-(prop-2-enylthio)-4-thieno[2,3-d]pyrimidinamine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5-dimethyl-2-[[2-(6-methyl-4-oxo-5-phenyl-3-thieno[2,3-d]pyrimidinyl)-1-oxoethyl]amino]-3-thiophenecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[3-(2-furanylmethyl)-2,4-dioxo-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b]pyrimidin-1-yl]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyclohexyl-2-hydrazinyl-7-(phenylmethyl)-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-(diethylamino)ethyl]-7,7-dimethyl-2-(4-methylphenyl)-5,8-dihydropyrano[4,3-d]pyrimidine-4-thione | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
oxacycle | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(butylamino)-3-(3-chlorophenyl)-7-methyl-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-yl)-2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,6-dimethyl-N-(thiophen-2-ylmethyl)-4-thieno[2,3-d]pyrimidinamine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1,3-dimethyl-2-benzimidazolylidene)-4-[(6-ethyl-4-thieno[2,3-d]pyrimidinyl)thio]-3-oxobutanenitrile | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(phenylmethyl)-2-sulfanylidene-1H-thieno[3,2-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methyl-6-thiophen-2-yl-4-isoxazolo[5,4-b]pyridinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
oxacycle | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[3-(4-methylphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]-N-(2-thiazolyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[3-(4-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-furanylmethyl)-2-(6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-d]pyrimidin-4-ylthio)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-chloro-N-(2-ethyl-4-oxo-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-3-yl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methyl-N-[(4-methylphenyl)methyl]-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-amine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-methoxyanilino)-2,5-dimethyl-6-thieno[2,3-d]pyrimidinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[(2-chlorophenyl)thio]methyl]-5-methyl-4-oxo-3H-thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(2-chlorophenyl)-2-(2-pyridinylmethyl)-3H-thieno[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[[4-cyclohexyl-5-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-5,6-dimethyl-3H-thieno[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,6-dimethyl-N-[2-methyl-2-(4-morpholinyl)propyl]-4-thieno[2,3-d]pyrimidinamine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[[2-[(5-methoxycarbonyl-2-furanyl)methoxy]-2-oxoethyl]thio]methyl]-5-methyl-4-oxo-3H-thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[[(5,6-dimethyl-4-thieno[2,3-d]pyrimidinyl)thio]methyl]-2-furancarboxylic acid methyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N4-isopropyl-7-methylthieno[3,2-d]pyrimidin-4-amine | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-amino-7,8,9,10-tetrahydro-6H-pyrimido[3,4]pyrrolo[3,5-a]azepine-11-carbonitrile | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-ethyl-7-methyl-2-sulfanylidene-6,9-dihydro-1H-pyrano[2,3]thieno[2,4-b]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[2-(dimethylamino)-2-thiophen-2-ylethyl]amino]-5-methyl-6-thieno[2,3-d]pyrimidinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[(1-ethyl-2-benzimidazolyl)thio]methyl]-5-methyl-4-oxo-3H-thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apramycin | | 2-deoxystreptamine derivative;
aminoglycoside;
organic heterobicyclic compound | antibacterial drug;
antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-5894 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(5,6-dimethyl-2-propyl-4-thieno[2,3-d]pyrimidinyl)thio]-1-(2-methyl-2,3-dihydroindol-1-yl)ethanone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-ethyl-6-methyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]-N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[2-furanyl(4-morpholinyl)methyl]-2-methyl-6-thiazolo[3,2-b][1,2,4]triazolol | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,8-dimethyl-4-oxo-7,8,9,10-tetrahydro-6H-thieno[1,2]pyrimido[4,5-a]azepine-2-carboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,7-dimethyl-2-(methylthio)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[2-[(2-ethoxy-2-oxoethyl)thio]-4-oxo-3-thieno[3,2-d]pyrimidinyl]-1-piperidinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-yl)-2-[[6-methyl-4-oxo-3-(phenylmethyl)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,5-dimethyl-4-(4-methyl-1-piperidinyl)-6-thieno[2,3-d]pyrimidinecarboxylic acid | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[[4-(dimethylamino)phenyl]methyl]-3-ethyl-N-(2-furanylmethyl)-5-methyl-4-oxo-6-thieno[2,3-d]pyrimidinecarboxamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-yl)-3-ethyl-5-methyl-4-oxo-6-thieno[2,3-d]pyrimidinecarboxamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[3-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)-1-oxopropyl]-1-piperazinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[3-(2-methoxyethyl)-6-methyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]-N-(2-oxolanylmethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-16990 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[1-oxo-6-(4-oxo-2-sulfanylidene-1H-thieno[3,2-d]pyrimidin-3-yl)hexyl]-1-piperazinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(4-amino-7-tert-butyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl)thio]acetic acid | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-chlorophenyl)-5-methyl-4-oxo-2,3-dihydro-1H-thieno[3,4-d]pyrimidine-7-carboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-ethyl-7-methyl-4-oxo-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]-N-(2-phenylethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[2-[(1,1-dioxo-3-thiolanyl)amino]-2-oxoethyl]thio]-2,5-dimethyl-6-thieno[2,3-d]pyrimidinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[2-furanyl(4-morpholinyl)methyl]-6-thiazolo[3,2-b][1,2,4]triazolol | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5-chloro-2-methoxyphenyl)-2-[[3-(2-methoxyethyl)-6-methyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-22688 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-furanyl-[4-[(6-hydroxy-2-methyl-5-thiazolo[3,2-b][1,2,4]triazolyl)-thiophen-2-ylmethyl]-1-piperazinyl]methanone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5-methyl-3-isoxazolyl)-2-[(6-methyl-4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)-N-(3-fluoro-4-methylphenyl)propanamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-methoxyphenyl)-3,5,6,7,8,9-hexahydrocyclohepta[2,3]thieno[2,4-b]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[(2,5,6-trimethyl-4-thieno[2,3-d]pyrimidinyl)thio]-2-oxolanone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[3-[2-(diethylamino)ethyl]-4-oxo-[1]benzothiolo[3,2-d]pyrimidin-2-yl]thio]-N-(phenylmethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,5-dimethyl-4-[[2-oxo-2-(4-phenylbutan-2-ylamino)ethyl]thio]-6-thieno[2,3-d]pyrimidinecarboxylic acid ethyl ester | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cornexistin | | cyclic dicarboxylic anhydride;
organic heterobicyclic compound;
secondary alpha-hydroxy ketone | herbicide;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| geldanamycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound | antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trandolaprilat | | dicarboxylic acid;
dipeptide;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trandolapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-[(4-fluorophenyl)methyl]-5,7-dimethyl-2H-pyrrolo[3,4-d]pyridazin-1-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manumycin | | enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol | antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aurachin c | | C-type aurachin;
hydroxylamines;
organic heterobicyclic compound;
quinolone | antibacterial agent;
bacterial metabolite;
EC 1.8.5.4 (sulfide:quinone reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asukamycin | | enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3,6-dimethyl-4-oxo-2-thieno[2,3-d]pyrimidinyl)thio]-N-(4-methylphenyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tanespimycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 404039 | | bridged compound;
dicarboxylic acid;
non-proteinogenic amino acid derivative;
organic heterobicyclic compound;
sulfone | antipsychotic agent;
anxiolytic drug;
dopamine agonist;
metabotropic glutamate receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PI3-Kinase alpha Inhibitor 2 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marizomib | | beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide | antineoplastic agent;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ceratamine a | | alkaloid;
aromatic ether;
cyclic ketone;
organic heterobicyclic compound;
organobromine compound;
secondary amino compound;
tertiary amine | antimitotic;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| complestatin | | cyclic ether;
heterodetic cyclic peptide;
indoles;
organic heterobicyclic compound;
organochlorine compound;
peptide antibiotic;
polyphenol | anti-HIV-1 agent;
antimicrobial agent;
HIV-1 integrase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-furanylmethyl)-2-[[4-oxo-3-[3-(1-pyrrolidinyl)propyl]-[1]benzothiolo[3,2-d]pyrimidin-2-yl]thio]acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-[butyl(ethyl)amino]propyl]-1-(9-fluoro-[1]benzothiolo[3,2-d]pyrimidin-4-yl)-4-piperidinecarboxamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(5,6-dimethyl-4-thieno[2,3-d]pyrimidinyl)amino]-1-(4-nitrophenyl)ethanol | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sm 164 | | benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles | antineoplastic agent;
apoptosis inducer;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiruchostatin b | | macrocyclic lactone;
organic disulfide;
organic heterobicyclic compound;
spiruchostatin | antineoplastic agent;
bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 3758309 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4-dimethyl-6-phenyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-[(2-fluorophenyl)methyl]-2-(1-hydroxyethyl)-4-methyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-[(3-methoxyphenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-bromo-6-[(2-chloro-6-fluorophenyl)methyl]-4-methyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-bromo-6-[(2,4-difluorophenyl)methyl]-4-methyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tropodithietic acid | | cyclic ketone;
monocarboxylic acid;
organic disulfide;
organic heterobicyclic compound;
organosulfur heterocyclic compound | antibacterial agent;
bacterial metabolite;
marine metabolite;
signalling molecule;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mycalamide b | | organic heterobicyclic compound;
oxacycle | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| streptolydigin | | bridged compound;
cyclic ketal;
enol;
monocarboxylic acid amide;
N-glycosyl compound;
organic heterobicyclic compound;
pyrrolidinone;
spiro-epoxide | antimicrobial agent;
bacterial metabolite;
EC 2.7.7.6 (RNA polymerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| allopurinol | | nucleobase analogue;
organic heterobicyclic compound | antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,4-Dihydrothieno[3,2-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-Methyl-3,4-dihydrothieno[3,2-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,n(4)-ethanocytosine | | organic heterobicyclic compound | mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,9-dimethyl-2-(phenylmethylthio)-1H-pyrido[2,3]thieno[2,4-b]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[(6-methyl-5-oxo-2H-1,2,4-triazin-3-yl)thio]methyl]-5,6,7,8-tetrahydro-3H-[1]benzothiolo[2,3-d]pyrimidin-4-one | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorendic acid | | bridged compound;
dicarboxylic acid;
organochlorine compound | carcinogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triethylenediamine | | bridged compound;
diamine;
saturated organic heterobicyclic parent;
tertiary amino compound | antioxidant;
catalyst;
reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cytisine | | alkaloid;
bridged compound;
lactam;
organic heterotricyclic compound;
secondary amino compound | nicotinic acetylcholine receptor agonist;
phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bicozamycin | | azabicycloalkane;
bridged compound | antibacterial agent;
antidiarrhoeal drug;
antiinfective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-bergamotene | | bridged compound;
polycyclic olefin;
sesquiterpene | plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tandospirone | | bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines | antidepressant;
anxiolytic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ecteinascidin 743 | | acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound | alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| megestrol acetate | | bridged compound;
organic heterotetracyclic compound;
secondary alcohol;
sesquiterpene lactone;
spiro compound;
tertiary alcohol;
tetrol | GABA antagonist;
neurotoxin;
phytogenic insecticide;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lurasidone | | 1,2-benzisothiazole;
bridged compound;
dicarboximide;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| stevioside | | beta-D-glucoside;
bridged compound;
diterpene glycoside;
ent-kaurane diterpenoid;
tetracyclic diterpenoid | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
hypoglycemic agent;
plant metabolite;
sweetening agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| steviol | | bridged compound;
ent-kaurane diterpenoid;
monocarboxylic acid;
tertiary allylic alcohol;
tetracyclic diterpenoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 16beta,17-dihydroxy-ent-kaurane-19-oic acid | | bridged compound;
diol;
ent-kaurane diterpenoid;
hydroxy monocarboxylic acid;
primary alcohol;
tertiary alcohol | anti-HIV agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sordaricin | | 3-oxo monocarboxylic acid;
aldehyde;
bridged compound;
primary alcohol;
tetracyclic diterpenoid | antifungal agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| komaroviquinone | | bridged compound;
lactol;
p-quinones;
tetracyclic diterpenoid | metabolite;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bicyclo(2.2.1)heptene | | bridged compound;
carbobicyclic compound;
cyclic olefin | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iwr-1 exo | | bridged compound;
dicarboximide | axin stabilizer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sf 2370 | | bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound | antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sr 144528 | | bridged compound;
monochlorobenzenes;
pyrazoles;
secondary carboxamide | CB2 receptor antagonist;
EC 2.3.1.26 (sterol O-acyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| catharanthine | | alkaloid ester;
bridged compound;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cedrene | | bridged compound;
carbotricyclic compound;
polycyclic olefin;
sesquiterpene | human urinary metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yunaconitine | | acetate ester;
aromatic ether;
benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound | antifeedant;
human urinary metabolite;
phytotoxin;
plant metabolite;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8,5'-cyclo-2'-deoxyadenosine | | aromatic amine;
bridged compound;
diol;
N-glycosyl compound;
organic heterotetracyclic compound | Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hu 308 | | aromatic ether;
bridged compound;
carbobicyclic compound;
primary allylic alcohol;
synthetic cannabinoid | anti-inflammatory agent;
antihypertensive agent;
apoptosis inhibitor;
bone density conservation agent;
CB2 receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sativene | | bridged compound;
sesquiterpene | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoylaconine | | benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound;
tetrol | phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dihydroagarofuran | | bridged compound;
cyclic ether;
eudesmane sesquiterpenoid;
organic heterotricyclic compound | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deoxyaconitine | | acetate ester;
benzoate ester;
bridged compound;
diol;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary amino compound | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxypaeoniflora | | 4-hydroxybenzoate ester;
beta-D-glucoside;
bridged compound;
cyclic acetal;
lactol;
monoterpene glycoside | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubusoside | | beta-D-glucoside;
bridged compound;
steviol glycoside;
tetracyclic diterpenoid | plant metabolite;
sweetening agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aspergillide b | | bridged compound;
cyclic ether;
macrolide;
secondary alcohol | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoylmesaconine | | benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound;
tetrol | analgesic;
antiinfective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| albiflorin | | benzoate ester;
beta-D-glucoside;
bridged compound;
gamma-lactone;
monoterpene glycoside;
secondary alcohol | neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvileucalin b | | bridged compound;
diterpenoid;
furans;
gamma-lactone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lycojapodine a | | alkaloid;
bridged compound;
cyclic ketone;
lactone;
organic heterotetracyclic compound | anti-HIV-1 agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iwr-1 endo | | benzamides;
bridged compound;
dicarboximide;
quinolines | axin stabilizer;
Wnt signalling inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide | | aromatic amide;
bridged compound;
olefinic compound;
organochlorine compound;
organofluorine compound;
pyrazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ledipasvir | | azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound | antiviral drug;
hepatitis C protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aspergillide a | | bridged compound;
cyclic ether;
macrolide;
secondary alcohol | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capilliposide b | | alpha-L-arabinopyranoside;
bridged compound;
cyclic ether;
diol;
hexacyclic triterpenoid;
hexanoate ester;
lactol;
secondary alcohol;
tetrasaccharide derivative;
triterpenoid saponin | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paeoniflorigenone | | alicyclic ketone;
benzoate ester;
bridged compound;
cyclic acetal;
lactol;
monoterpenoid | neuromuscular agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8,5'-cyclo-2'-deoxyguanosine | | aromatic amine;
bridged compound;
diol;
N-glycosyl compound;
organic heterotetracyclic compound | Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-aminoadipic acid | | amino dicarboxylic acid;
dicarboxylic fatty acid;
non-proteinogenic alpha-amino acid | Caenorhabditis elegans metabolite;
mammalian metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methylglutamic acid | | amino dicarboxylic acid;
glutamic acid derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxyaspartic acid | | amino dicarboxylic acid;
aspartic acid derivative;
C4-dicarboxylic acid;
hydroxy-amino acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iminodiacetic acid | | amino dicarboxylic acid;
glycine derivative;
non-proteinogenic alpha-amino acid | chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-methylaspartate | | amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound | neurotransmitter agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| edda | | amino dicarboxylic acid;
ethylenediamine derivative;
glycine derivative;
polyamino carboxylic acid | bacterial xenobiotic metabolite;
chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminomalonic acid | | amino dicarboxylic acid | Daphnia magna metabolite;
human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-aminopimelic acid | | amino dicarboxylic acid;
non-proteinogenic alpha-amino acid | bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| octopine | | amino acid opine;
amino dicarboxylic acid;
D-alpha-amino acid zwitterion;
D-arginine derivative;
guanidines;
secondary amino compound | animal metabolite;
xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-s-cysteinyldopa | | amino dicarboxylic acid;
aryl sulfide;
catechols;
diamine;
L-tyrosine derivative;
S-conjugate;
S-organyl-L-cysteine | human urinary metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alanopine | | amino acid opine;
amino dicarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxalylglycine | | amino dicarboxylic acid;
N-acylglycine | EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leukotriene e4 | | amino dicarboxylic acid;
L-cysteine thioether;
leukotriene;
non-proteinogenic L-alpha-amino acid;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dysiherbaine | | amino dicarboxylic acid;
furopyran;
hydroxy carboxylic acid;
secondary amino compound | animal metabolite;
excitatory amino acid agonist;
marine metabolite;
neurotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neodysiherbaine a | | amino dicarboxylic acid;
diol;
furopyran;
hydroxy carboxylic acid | animal metabolite;
excitatory amino acid agonist;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| succinyladenosine | | adenosines;
amino dicarboxylic acid;
L-aspartic acid derivative | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| xanthurenic acid | | dihydroxyquinoline;
quinolinemonocarboxylic acid | animal metabolite;
iron chelator;
metabotropic glutamate receptor agonist;
vesicular glutamate transport inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-amino-4-phosphonobutyric acid | | non-proteinogenic L-alpha-amino acid;
phosphonic acids | metabotropic glutamate receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cysteine sulfinic acid | | organosulfinic acid;
S-substituted L-cysteine | Escherichia coli metabolite;
human metabolite;
metabotropic glutamate receptor agonist;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amn082 | | benzenes;
diamine;
diarylmethane;
secondary amino compound | metabotropic glutamate receptor agonist;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 404039 | | bridged compound;
dicarboxylic acid;
non-proteinogenic amino acid derivative;
organic heterobicyclic compound;
sulfone | antipsychotic agent;
anxiolytic drug;
dopamine agonist;
metabotropic glutamate receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride | | hydrochloride | geroprotector;
metabotropic glutamate receptor agonist;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dihydrolipoic acid | | thio-fatty acid | antioxidant;
human metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| creatine | | glycine derivative;
guanidines;
zwitterion | geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,5-dimethyl-1-pyrroline-1-oxide | | 1-pyrroline nitrones | neuroprotective agent;
spin trapping reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethylisopropylamiloride | | aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound | anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methoxytryptamine | | aromatic ether;
primary amino compound;
tryptamines | 5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chlorokynurenic acid | | organochlorine compound;
quinolinemonocarboxylic acid | neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cilostazol | | lactam;
tetrazoles | anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dantrolene | | hydrazone;
imidazolidine-2,4-dione | muscle relaxant;
neuroprotective agent;
ryanodine receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ebselen | | benzoselenazole | anti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etazolate | | ethyl ester;
hydrazone;
pyrazolopyridine | alpha-secretase activator;
antidepressant;
antipsychotic agent;
anxiolytic drug;
GABA agent;
neuroprotective agent;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethoxyquin | | aromatic ether;
quinolines | antifungal agrochemical;
food antioxidant;
genotoxin;
geroprotector;
herbicide;
Hsp90 inhibitor;
neuroprotective agent;
UDP-glucuronosyltransferase activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| felbamate | | carbamate ester | anticonvulsant;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fasudil | | isoquinolines;
N-sulfonyldiazepane | antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kynurenic acid | | monohydroxyquinoline;
quinolinemonocarboxylic acid | G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| memantine | | adamantanes;
primary aliphatic amine | antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| palmidrol | | endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine | anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pj-34 | | phenanthridines;
secondary carboxamide;
tertiary amino compound | angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenylbutyric acid, sodium salt | | organic sodium salt | EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylene blue | | organic chloride salt | acid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylparaben | | paraben | antifungal agent;
antimicrobial food preservative;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cytidine diphosphate choline | | nucleotide-(amino alcohol)s;
phosphocholines | human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetramethylpyrazine | | alkaloid;
pyrazines | antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pn 401 | | acetate ester;
uridines | neuroprotective agent;
orphan drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| argon | | monoatomic argon;
noble gas atom;
p-block element atom | food packaging gas;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid | | chromanol;
monocarboxylic acid;
phenols | antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radical scavenger;
Wnt signalling inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tenocyclidine | | piperidines;
tertiary amino compound;
thiophenes | central nervous system stimulant;
hallucinogen;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baicalin | | dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative | antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epigallocatechin gallate | | flavans;
gallate ester;
polyphenol | antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norvaline | | 2-aminopentanoic acid;
L-alpha-amino acid zwitterion | bacterial metabolite;
hypoglycemic agent;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrrolidine dithiocarbamate | | dithiocarbamic acids;
pyrrolidines | anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pinocembrin | | (2S)-flavan-4-one;
dihydroxyflavanone | antineoplastic agent;
antioxidant;
metabolite;
neuroprotective agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sesamin | | benzodioxoles;
furofuran;
lignan | antineoplastic agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fangchinoline | | aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle | anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rivastigmine | | carbamate ester;
tertiary amino compound | cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loganin | | beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol | anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-ketocholesterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
7-oxo steroid;
cholestanoid | neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenylisopropyladenosine | | aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound | adenosine A1 receptor agonist;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| delta(9)-tetrahydrocannabinolic acid | | benzochromene;
diterpenoid;
hydroxy monocarboxylic acid;
phytocannabinoid;
polyketide | anti-inflammatory agent;
biomarker;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| galgravin | | aryltetrahydrofuran;
dimethoxybenzene;
lignan;
ring assembly | bone density conservation agent;
neuroprotective agent;
plant metabolite;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s-methylthiocitrulline | | imidothiocarbamic ester;
L-arginine derivative;
L-ornithine derivative;
non-proteinogenic L-alpha-amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ta 0910 | | oligopeptide | analgesic;
neuroprotective agent;
nootropic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgp 42112a | | benzyl ester;
oligopeptide;
pyridinecarboxamide | angiotensin receptor agonist;
anti-inflammatory agent;
antineoplastic agent;
neuroprotective agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2,2,2-trimethylhydrazine)propionate | | ammonium betaine | cardioprotective agent;
EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 27-hydroxycholesterol | | 26-hydroxycholesterol | apoptosis inducer;
human metabolite;
mouse metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubimaillin | | benzochromene;
methyl ester;
phenols | acyl-CoA:cholesterol acyltransferase 2 inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
NF-kappaB inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyanidin | | 5-hydroxyanthocyanidin | antioxidant;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ilomastat | | hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lanthionine ketimine | | 1,4-thiazine;
dicarboxylic acid;
sulfur-containing amino acid | anti-inflammatory agent;
human urinary metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tempol | | aminoxyls;
hydroxypiperidine | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| schizandrin b | | aromatic ether;
cyclic acetal;
organic heterotetracyclic compound;
oxacycle;
tannin | anti-asthmatic agent;
anti-inflammatory agent;
antilipemic drug;
antioxidant;
apoptosis inhibitor;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvigenin | | monohydroxyflavone;
trimethoxyflavone | antilipemic drug;
antineoplastic agent;
apoptosis inhibitor;
autophagy inducer;
hypoglycemic agent;
immunomodulator;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fasudil hydrochloride | | hydrochloride | antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
neuroprotective agent;
nootropic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methylthiohexyl isothiocyanate | | isothiocyanate;
methyl sulfide | antineoplastic agent;
Arabidopsis thaliana metabolite;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anacardic acid | | hydroxy monocarboxylic acid;
hydroxybenzoic acid | anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb 203580 | | imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dizocilpine | | secondary amino compound;
tetracyclic antidepressant | anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| memantine hydrochloride | | hydrochloride | antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 3,4-dihydroxybenzoate | | catechols;
methyl ester | antioxidant;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carnosine | | amino acid zwitterion;
dipeptide | anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| theanine | | amino acid zwitterion;
N(5)-alkyl-L-glutamine | geroprotector;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neriifolin | | cardenolide glycoside | cardiotonic drug;
neuroprotective agent;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside re | | 12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
nephroprotective agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rg1 | | 12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid | neuroprotective agent;
pro-angiogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| notoginsenoside r1 | | 12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid | antioxidant;
apoptosis inducer;
neuroprotective agent;
phytoestrogen;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol | | carbotetracyclic compound;
polyphenol | estrogen receptor agonist;
estrogen receptor antagonist;
geroprotector;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimethyloxalylglycine | | glycine derivative;
methyl ester;
secondary carboxamide | EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhapontin | | rhaponticin | angiogenesis inhibitor;
anti-allergic agent;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
hypoglycemic agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glycerylphosphorylcholine | | phosphocholines;
sn-glycerol 3-phosphates | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neuroprotective agent;
parasympatholytic;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| huperzine a | | organic heterotricyclic compound;
primary amino compound;
pyridone;
sesquiterpene alkaloid | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
neuroprotective agent;
nootropic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aurapten | | coumarins;
monoterpenoid | antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
dopaminergic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
gamma-secretase modulator;
gastrointestinal drug;
hepatoprotective agent;
matrix metalloproteinase inhibitor;
neuroprotective agent;
plant metabolite;
PPARalpha agonist;
vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide | | pyrazines;
sulfonamide;
thiophenes | necroptosis inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rasagiline | | indanes;
secondary amine;
terminal acetylenic compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ferrostatin-1 | | ethyl ester;
primary arylamine;
substituted aniline | antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | | benzenes;
thiadiazolidine | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb 415286 | | C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline | antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gossypin | | 7-hydroxyflavonol;
glycosyloxyflavone;
monosaccharide derivative;
pentahydroxyflavone | neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hinokiflavone | | aromatic ether;
biflavonoid;
hydroxyflavone | antineoplastic agent;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| morin | | 7-hydroxyflavonol;
pentahydroxyflavone | angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pterostilbene | | diether;
methoxybenzenes;
stilbenol | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| caffeic acid phenethyl ester | | alkyl caffeate ester | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acteoside | | catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol | anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tocotrienol, alpha | | tocotrienol;
vitamin E | ferroptosis inhibitor;
human metabolite;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| menatetrenone | | menaquinone | anti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| arachidonyl-2-chloroethylamide | | fatty amide;
organochlorine compound;
secondary carboxamide;
synthetic cannabinoid | CB1 receptor agonist;
CB2 receptor agonist;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone | | morpholines;
naphthyl ketone;
organic heterotricyclic compound;
synthetic cannabinoid | analgesic;
apoptosis inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cannabigerol | | phytocannabinoid;
resorcinols | anti-inflammatory agent;
antibacterial agent;
antioxidant;
appetite enhancer;
cannabinoid receptor agonist;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetrahydroxycurcumin | | beta-diketone;
catechols;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dizocilpine maleate | | maleate salt;
tetracyclic antidepressant | anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sdz eaa 494 | | monocarboxylic acid;
olefinic compound;
phosphonic acids;
piperazinecarboxylic acid;
tertiary amino compound | anticonvulsant;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| germacrone | | germacrane sesquiterpenoid;
olefinic compound | androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvianolic acid B | | 1-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol | anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 25-6981 | | benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound | anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bis(7)-tacrine | | secondary amino compound | apoptosis inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jasplakinolide | | cyclodepsipeptide;
phenols | actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ursodoxicoltaurine | | bile acid taurine conjugate | anti-inflammatory agent;
apoptosis inhibitor;
bone density conservation agent;
cardioprotective agent;
human metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 779976 | | benzimidazoles;
indoles;
piperidinecarboxamide;
primary amino compound;
secondary carboxamide | neuroprotective agent;
somatostatin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rb1 | | ginsenoside;
glycoside;
tetracyclic triterpenoid | anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| NNC 55-0396 (free base) | | benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glu-asp-arg | | tripeptide | neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-arachidonoyl l-serine | | N-(fatty acyl)-L-alpha-amino acid | cannabinoid receptor agonist;
mammalian metabolite;
neuroprotective agent;
pro-angiogenic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-benzylhexadecanamide | | macamide;
secondary carboxamide | EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| np 031112 | | benzenes;
naphthalenes;
thiadiazolidine | anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cytidine diphosphate choline | | nucleotide-(amino alcohol)s;
phosphocholines | human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rd | | beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid | anti-inflammatory drug;
apoptosis inducer;
immunosuppressive agent;
neuroprotective agent;
plant metabolite;
vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glycoursodeoxycholic acid | | bile acid glycine conjugate;
N-acylglycine | human blood serum metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rb3 | | 12beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid | antidepressant;
antioxidant;
cardioprotective agent;
neuroprotective agent;
NMDA receptor antagonist;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| astragaloside IV | | pentacyclic triterpenoid;
triterpenoid saponin | anti-inflammatory agent;
antioxidant;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
neuroprotective agent;
plant metabolite;
pro-angiogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| protectin d1 | | dihydroxydocosahexaenoic acid;
protectin;
secondary allylic alcohol | anti-inflammatory agent;
apoptosis inhibitor;
hepatoprotective agent;
human xenobiotic metabolite;
neuroprotective agent;
PPARgamma agonist;
specialised pro-resolving mediator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| forapin | | peptidyl amide;
polypeptide | animal metabolite;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.13 (protein kinase C) inhibitor;
hepatoprotective agent;
neuroprotective agent;
venom | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| astressin | | homodetic cyclic peptide;
polypeptide | corticotropin-releasing factor receptor antagonist;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| liraglutide | | lipopeptide;
polypeptide | glucagon-like peptide-1 receptor agonist;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nnc 55-0396 | | hydrochloride | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| albiflorin | | benzoate ester;
beta-D-glucoside;
bridged compound;
gamma-lactone;
monoterpene glycoside;
secondary alcohol | neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SL-327 | | (trifluoromethyl)benzenes;
enamine;
nitrile;
organic sulfide;
primary amino compound;
substituted aniline | EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apelin-13 peptide | | oligopeptide | antihypertensive agent;
autophagy inhibitor;
biomarker;
human metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe | | polypeptide | apoptosis inhibitor;
human metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oleuropein aglycone | | catechols;
diester;
lactol;
methyl ester;
pyrans;
secoiridoid | anti-inflammatory agent;
antioxidant;
mTOR inhibitor;
neuroprotective agent;
plant metabolite;
TRPA1 channel agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| semaglutide | | lipopeptide;
polypeptide | anti-obesity agent;
appetite depressant;
glucagon-like peptide-1 receptor agonist;
hypoglycemic agent;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| maysin | | disaccharide derivative;
flavone C-glycoside;
secondary alpha-hydroxy ketone;
tetrahydroxyflavone | insecticide;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ((5z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4h-imidazol-4-one) | | benzodioxoles;
imidazolone;
substituted aniline | autophagy inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.12.1 (dual-specificity kinase) inhibitor;
neuroprotective agent;
nootropic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apelin-12 peptide | | oligopeptide | biomarker;
human blood serum metabolite;
human metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzquinamide | | monocarboxylic acid amide | antiemetic;
antipsychotic agent;
H1-receptor antagonist;
muscarinic antagonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlormezanone | | 1,3-thiazine;
lactam;
monochlorobenzenes;
sulfone | antipsychotic agent;
anxiolytic drug;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loxapine | | dibenzooxazepine | antipsychotic agent;
dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methiothepin | | aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound | antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ritanserin | | organofluorine compound;
piperidines;
thiazolopyrimidine | antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiperone | | aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound | alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulpiride | | benzamides;
N-alkylpyrrolidine;
sulfonamide | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azaperone | | aminopyridine;
aromatic ketone;
monofluorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
tertiary amino compound | antipsychotic agent;
dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ziprasidone | | 1,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines | antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| levosulpiride | | sulpiride | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dapiprazole | | N-alkylpiperazine;
N-arylpiperazine;
pyridines | alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride | | aromatic ether;
hydrochloride;
methoxybenzenes;
tertiary amino compound | antipsychotic agent;
receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pimavanserin | | aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas | 5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alprazolam | | organochlorine compound;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clobazam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clonazepam | | 1,4-benzodiazepinone;
monochlorobenzenes | anticonvulsant;
anxiolytic drug;
GABA modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorazepate | | 1,4-benzodiazepinone | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nordazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| estazolam | | triazoles;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludiazepam | | 1,4-benzodiazepinone;
organochlorine compound;
organofluorine compound | anxiolytic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flunitrazepam | | 1,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes | anxiolytic drug;
GABAA receptor agonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flurazepam | | 1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound | anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxyzine | | hydroxyether;
monochlorobenzenes;
N-alkylpiperazine | anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxazepam | | 1,4-benzodiazepinone;
organochlorine compound | anxiolytic drug;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zaleplon | | nitrile;
pyrazolopyrimidine | anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| didesethylflurazepam | | 1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
primary amino compound | anticonvulsant;
anxiolytic drug;
drug metabolite;
GABAA receptor agonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buspirone hydrochloride | | hydrochloride | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adinazolam | | triazolobenzodiazepine | anticonvulsant;
antidepressant;
anxiolytic drug;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midazolam hydrochloride | | hydrochloride;
imidazobenzodiazepine | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paroxetine hydrochloride | | hydrochloride | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glutaurine | | dipeptide zwitterion;
dipeptide;
L-glutamine derivative;
sulfonic acid | anticonvulsant;
anxiolytic drug;
hormone;
human metabolite;
mammalian metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amperozide | | diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas | anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amperozide hydrochloride | | hydrochloride | anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tandospirone | | bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines | antidepressant;
anxiolytic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride | | hydrochloride | anxiolytic drug;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spinosin | | dihydroxyflavone;
flavone C-glycoside;
monomethoxyflavone | anxiolytic drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clorazepate dipotassium | | potassium salt | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ANA-12 | | 1-benzothiophenes;
caprolactams;
secondary carboxamide | antidepressant;
anxiolytic drug;
tropomyosin-related kinase B receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methyl-2-(phenylethynyl)pyridine | | acetylenic compound;
methylpyridines | anxiolytic drug;
metabotropic glutamate receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clavulanic acid | | oxapenam | antibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluvoxamine | | (trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime | antidepressant;
anxiolytic drug;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paroxetine maleate | | maleate salt | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-6-(phenylethynyl)pyridine hydrochloride | | hydrochloride | anxiolytic drug;
metabotropic glutamate receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vortioxetine | | aryl sulfide;
N-arylpiperazine | antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| demethylmirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
human xenobiotic metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
Ligands for glutamate receptors: design and therapeutic prospects.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
Ligands for glutamate receptors: design and therapeutic prospects.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.Journal of medicinal chemistry, , Jan-25, Volume: 50, Issue:2, 2007
(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
Ligands for glutamate receptors: design and therapeutic prospects.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists fJournal of medicinal chemistry, , Mar-25, Volume: 42, Issue:6, 1999
(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
Ligands for glutamate receptors: design and therapeutic prospects.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 22, Issue:5, 2012
Ligands for glutamate receptors: design and therapeutic prospects.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 22, Issue:5, 2012
(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 2004 | 2014 | 13.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| 3,4-dihydroxyphenylacetic acid | | catechols;
dihydroxyphenylacetic acid | human metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycine | | alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical | 2001 | 2021 | 15.6 | low | 0 | 0 | 0 | 6 | 3 | 1 |
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenethylamine | | alkaloid;
aralkylamine;
phenylethylamine | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sarcosine | | N-alkylglycine zwitterion;
N-alkylglycine;
N-methyl-amino acid;
N-methylglycines | Escherichia coli metabolite;
glycine receptor agonist;
glycine transporter 1 inhibitor;
human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| toluene | | methylbenzene;
toluenes;
volatile organic compound | cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent | 2003 | 2015 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-amino-5-phosphonovalerate | | non-proteinogenic alpha-amino acid | NMDA receptor antagonist | 2008 | 2019 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-iodo-2,5-dimethoxyphenylisopropylamine | | amphetamines;
dimethoxybenzene;
organoiodine compound | | 2002 | 2018 | 14.6 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| ibotenic acid | | non-proteinogenic alpha-amino acid | neurotoxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-carboxy-3-hydroxyphenylglycine | | hydroxybenzoic acid | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| homovanillic acid | | guaiacols;
monocarboxylic acid | human metabolite;
mouse metabolite | 2000 | 2001 | 23.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| hydroxyindoleacetic acid | | indole-3-acetic acids | drug metabolite;
human metabolite;
mouse metabolite | 2000 | 2001 | 23.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benoxathian | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clomipramine | | dibenzoazepine | anticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amphetamine | | primary amine | | 2000 | 2018 | 15.9 | low | 0 | 0 | 1 | 5 | 3 | 0 |
| diazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| racemetirosine | | | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| domperidone | | benzimidazoles;
heteroarylpiperidine | antiemetic;
dopaminergic antagonist | 2008 | 2011 | 14.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| erythrosine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flumazenil | | ethyl ester;
imidazobenzodiazepine;
organofluorine compound | antidote to benzodiazepine poisoning;
GABA antagonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2008 | 2016 | 11.2 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 1-methyl-3-isobutylxanthine | | 3-isobutyl-1-methylxanthine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ketamine | | cyclohexanones;
monochlorobenzenes;
secondary amino compound | analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic | 2003 | 2019 | 12.5 | low | 0 | 0 | 0 | 4 | 9 | 0 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | | chromones;
morpholines;
organochlorine compound | autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| entinostat | | benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxidopamine | | benzenetriol;
catecholamine;
primary amino compound | drug metabolite;
human metabolite;
neurotoxin | 2002 | 2003 | 21.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| pd 98059 | | aromatic amine;
monomethoxyflavone | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2001 | 2013 | 17.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pentoxifylline | | oxopurine | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenmetrazine | | morpholines | metabolite;
sympathomimetic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| potassium chloride | | inorganic chloride;
inorganic potassium salt;
potassium salt | fertilizer | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| propentofylline | | oxopurine | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| riluzole | | benzothiazoles | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 2000 | 2014 | 19.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| ritanserin | | organofluorine compound;
piperidines;
thiazolopyrimidine | antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| saccharin | | 1,2-benzisothiazole;
N-sulfonylcarboxamide | environmental contaminant;
sweetening agent;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| corticosterone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lysergic acid diethylamide | | ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound | dopamine agonist;
hallucinogen;
serotonergic agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dextroamphetamine | | 1-phenylpropan-2-amine | adrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent | 1999 | 2014 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| pilocarpine | | pilocarpine | antiglaucoma drug | 2004 | 2014 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alanine | | alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid | EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite | 2012 | 2015 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| serine | | L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aspartic acid | | aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
mouse metabolite;
neurotransmitter | 2012 | 2018 | 9.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2006 | 2023 | 11.7 | low | 0 | 0 | 0 | 5 | 3 | 1 |
| apomorphine | | aporphine alkaloid | alpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trifluoroethanol | | fluoroalcohol | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 1999 | 2018 | 17.2 | low | 0 | 0 | 3 | 6 | 4 | 0 |
| quinoxalines | | mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xanthenes | | xanthene | | 2000 | 2021 | 14.9 | low | 0 | 0 | 2 | 16 | 12 | 1 |
| pyrroles | | pyrrole;
secondary amine | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diethylenetriamine | | polyazaalkane;
triamine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2010 | 2019 | 11.9 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| fluorobenzenes | | monofluorobenzenes | NMR chemical shift reference compound | 2008 | 2018 | 10.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| kainic acid | | dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid | antinematodal drug;
excitatory amino acid agonist | 1999 | 2001 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| gluconic acid | | gluconic acid | chelator;
Penicillium metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| copper gluconate | | organic molecular entity | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methoxyhydroxyphenylglycol | | methoxybenzenes;
phenols | | 2008 | 2018 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-methylaspartate | | amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound | neurotransmitter agent | 1999 | 2018 | 18.2 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2003 | 2021 | 12.3 | low | 0 | 0 | 0 | 11 | 13 | 2 |
| colforsin | | acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol | adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| eticlopride | | salicylamides | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glucose, (beta-d)-isomer | | D-glucopyranose | epitope;
mouse metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| thiazolyl blue | | organic bromide salt | colorimetric reagent;
dye | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cholesteryl succinate | | cholestane ester;
dicarboxylic acid monoester;
hemisuccinate | detergent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| triazoles | | 1,2,3-triazole | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pentafluorobenzoyl chloride | | acyl chloride;
perfluorinated compound | chromatographic reagent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| d-aspartic acid | | aspartic acid;
D-alpha-amino acid | mouse metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 2007 | 2016 | 13.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| 3,4-dihydroxyphenylglycol | | catechols;
tetrol | metabolite;
mouse metabolite | 2008 | 2018 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| diosgenin | | 3beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal | antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dodecyl-beta-d-maltoside | | disaccharide derivative;
glycoside | detergent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 2-(2,3-dicarboxycyclopropyl)glycine | | | | 2001 | 2021 | 15.3 | low | 0 | 0 | 0 | 4 | 1 | 1 |
| proline | | amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid | algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isospaglumic acid | | dipeptide | human metabolite | 2006 | 2022 | 9.6 | low | 0 | 0 | 0 | 2 | 1 | 2 |
| osemozotan | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| eglumetad | | L-alpha-amino acid | | 1999 | 2021 | 17.8 | medium | 0 | 0 | 5 | 5 | 3 | 1 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2004 | 2020 | 12.3 | low | 0 | 0 | 0 | 8 | 8 | 0 |
| alpha-methyl-4-carboxyphenylglycine | | non-proteinogenic alpha-amino acid | metabotropic glutamate receptor antagonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dactinomycin | | actinomycin | mutagen | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vu 0155041 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-methyl-2-(phenylethynyl)pyridine | | acetylenic compound;
methylpyridines | anxiolytic drug;
metabotropic glutamate receptor antagonist | 2004 | 2019 | 14.4 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| raclopride | | salicylamides | | 2009 | 2011 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sch 23390 | | benzazepine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline | | naphthalenes;
sulfonic acid derivative | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,4-dicarboxyphenylglycine | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-aminopyrrolidine-2,4-dicarboxylic acid | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-chloro-5-hydroxyphenylglycine | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-cyano-7-nitroquinoxaline-2,3-dione | | quinoxaline derivative | | 2003 | 2012 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vitamin k 1 | | phylloquinones;
vitamin K | cofactor;
human metabolite;
plant metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 2008 | 2019 | 9.6 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| mdl 100907 | | | | 2008 | 2018 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methylazoxymethanol acetate | | azoxy compound | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| heroin | | morphinane alkaloid | mu-opioid receptor agonist;
opioid analgesic;
prodrug | 2005 | 2006 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tetrodotoxin | | azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid | animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker | 2003 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| dizocilpine maleate | | maleate salt;
tetracyclic antidepressant | anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist | 2003 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 7 | 1 |
| staurosporine | | ammonium ion derivative | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)piperidine | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(4-(2-methoxyphenoxy)phenyl)-n-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine | | | | 2005 | 2012 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| biphenyl-indanone a | | biphenyls | | 2010 | 2021 | 8.5 | high | 0 | 0 | 0 | 1 | 2 | 1 |
| l 838,417 | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cgp 55845a | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ly 389795 | | | | 1999 | 2005 | 23.0 | high | 0 | 0 | 2 | 3 | 0 | 0 |
| phenobarbital sodium | | | | 2006 | 2010 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ly 341495 | | | | 2000 | 2021 | 14.9 | medium | 0 | 0 | 2 | 16 | 12 | 1 |
| lurasidone hydrochloride | | hydrochloride | adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cp 154526 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n,n'-dibenzhydrylethane-1,2-diamine dihydrochloride | | hydrochloride | geroprotector;
metabotropic glutamate receptor agonist;
neuroprotective agent | 2009 | 2013 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| diosgenin glucoside | | hexacyclic triterpenoid;
monosaccharide derivative;
spiroketal;
sterol 3-beta-D-glucoside | metabolite | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| scopolamine hydrobromide | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cytochrome c-t | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iberiotoxin | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| picrotoxin | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycolipids | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| piperidines | | | | 2008 | 2018 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| minocycline | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| epidermal growth factor | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kaolinite | | aluminosilicate mineral;
mixture | antidiarrhoeal drug;
excipient | 2015 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| transforming growth factor beta | | | | 2000 | 2010 | 20.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| 2-phytyl-1,4-naphthoquinone | | phylloquinones | | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclin d1 | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclic gmp | | 3',5'-cyclic purine nucleotide;
guanyl ribonucleotide | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guanosine diphosphate | | guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate | Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guanosine 5'-o-(3-thiotriphosphate) | | nucleoside triphosphate analogue | | 2003 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 2000 | 2020 | 15.8 | low | 0 | 0 | 3 | 2 | 6 | 0 |
| olanzapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| guanosine 5'-o-(2-thiodiphosphate) | | nucleoside diphosphate analogue | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Absence Seizure | 0 | | 1999 | 2004 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Absence Status | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Academic Disorder, Developmental | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ache | 0 | | 2005 | 2019 | 12.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Acute Brain Injuries | 0 | | 2003 | 2022 | 13.7 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| Acute Confusional Senile Dementia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Disease | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Post-Traumatic Stress Disorder | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ADDH | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adipocere | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adjuvant Arthritis | 0 | | 2015 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Age-Related Memory Disorders | 0 | | 2013 | 2019 | 9.0 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| Aging | 0 | | 2012 | 2014 | 11.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Akinetic-Rigid Variant of Huntington Disease | 0 | | 2004 | 2021 | 10.5 | low | 0 | 0 | 0 | 1 | 3 | 2 |
| Alcohol Abuse | 0 | | 2006 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Alcohol Drinking | 0 | | 2005 | 2018 | 12.0 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| Alcohol Withdrawal Seizures | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Alcoholism | 0 | | 2006 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Allodynia | 0 | | 2002 | 2009 | 18.0 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| ALS - Amyotrophic Lateral Sclerosis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Alzheimer Disease | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Amyotrophic Lateral Sclerosis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anoxemia | 0 | | 1999 | 2022 | 14.7 | low | 0 | 0 | 1 | 1 | 0 | 1 |
| Anoxia-Ischemia, Brain | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Anoxia, Brain | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anxiety | 0 | | 2006 | 2015 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Arterial Diseases, Carotid | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Arterial Obstructive Diseases | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Arterial Occlusive Diseases | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Arthralgia | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Asphyxia | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Ataxia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Atherosclerotic Parkinsonism | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Atrophy | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Attention Deficit Disorder with Hyperactivity | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Benign Neoplasms, Brain | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Pressure, High | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Brain Diseases | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Disorders | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Edema | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Injuries | 0 | | 2003 | 2022 | 13.7 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| Brain Ischemia | 0 | | 1999 | 2001 | 24.2 | low | 0 | 0 | 3 | 1 | 0 | 0 |
| Brain Neoplasms | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Swelling | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carotid Artery Diseases | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cerebral Infarction, Middle Cerebral Artery | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cerebral Ischemia | 0 | | 1999 | 2001 | 24.2 | low | 0 | 0 | 3 | 1 | 0 | 0 |
| Chemical Dependence | 0 | | 2013 | 2019 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cocaine Abuse | 0 | | 2004 | 2018 | 13.1 | low | 0 | 0 | 0 | 7 | 6 | 0 |
| Cocaine-Related Disorders | 0 | | 2004 | 2018 | 13.1 | low | 0 | 0 | 0 | 7 | 6 | 0 |
| Cognition Disorders | 0 | | 2009 | 2010 | 14.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Cognitive Decline | 0 | | 2018 | 2019 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cognitive Dysfunction | 0 | | 2018 | 2019 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Convulsions, Grand Mal | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Delayed Effects, Prenatal Exposure | 0 | | 2012 | 2018 | 9.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Dementia Praecox | 0 | | 2002 | 2018 | 12.9 | low | 0 | 0 | 0 | 7 | 9 | 0 |
| Depression | 0 | | 2008 | 2019 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Depression, Endogenous | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Depressive Disorder | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Exacerbation | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Models, Animal | 0 | | 2003 | 2021 | 12.6 | medium | 0 | 0 | 0 | 15 | 18 | 1 |
| Drug Abuse, Intravenous | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Drug Withdrawal Symptoms | 0 | | 2007 | 2019 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Dyskinesia, Drug-Induced | 0 | | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Dyskinesia, Medication-Induced | 0 | | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Epilepsy, Tonic-Clonic | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fever | 0 | | 2012 | 2019 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Glial Cell Tumors | 0 | | 2003 | 2014 | 15.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Glioma | 0 | | 2003 | 2014 | 15.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Heroin Abuse | 0 | | 2004 | 2006 | 19.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Heroin Dependence | 0 | | 2004 | 2006 | 19.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Huntington Disease | 0 | | 2004 | 2021 | 10.5 | low | 0 | 0 | 0 | 1 | 3 | 2 |
| Hyperactivity, Motor | 0 | | 2003 | 2018 | 15.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| Hyperprolactinaemia | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperprolactinemia | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypertension | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypesthesia | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypoxia | 0 | | 1999 | 2022 | 14.7 | low | 0 | 0 | 1 | 1 | 0 | 1 |
| Hypoxia-Ischemia, Brain | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Infarction, Middle Cerebral Artery | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Inflammation | 0 | | 2002 | 2011 | 17.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Innate Inflammatory Response | 0 | | 2002 | 2011 | 17.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Joint Pain | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Learning Disabilities | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Memory Disorders | 0 | | 2013 | 2019 | 9.0 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| MPTP Neurotoxicity Syndrome | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Muscle Contraction | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Nerve Degeneration | 0 | | 2001 | 2010 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Nerve Pain | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuralgia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuralgia, Sciatic | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuroblastoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Nicotine Addiction | 0 | | 2007 | 2016 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Pain | 0 | | 2005 | 2019 | 12.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Parkinson Disease, Secondary | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pregnancy | 0 | | 2012 | 2020 | 8.8 | low | 0 | 0 | 0 | 0 | 5 | 0 |
| Psychoses | 0 | | 2004 | 2014 | 13.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Psychotic Disorders | 0 | | 2004 | 2014 | 13.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Pyrexia | 0 | | 2012 | 2019 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Recrudescence | 0 | | 2004 | 2019 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Retinal Diseases | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Schizophrenia | 0 | | 2002 | 2018 | 12.9 | low | 0 | 0 | 0 | 7 | 9 | 0 |
| Sciatica | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Seizures | 0 | | 1999 | 2004 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Status Epilepticus | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Stress Disorders, Post-Traumatic | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Substance Withdrawal Syndrome | 0 | | 2007 | 2019 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Substance-Related Disorders | 0 | | 2013 | 2019 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Suffocation | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Tobacco Use Disorder | 0 | | 2007 | 2016 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Weight Gain | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Astroglial mGlu3 receptors promote alpha-secretase-mediated amyloid precursor protein cleavage.Neuropharmacology, , Volume: 79, 2014
Regulation of connexin 36 expression during development.Neuroscience letters, , Mar-28, Volume: 513, Issue:1, 2012
Nicotine exposure during adolescence leads to short- and long-term changes in spike timing-dependent plasticity in rat prefrontal cortex.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Aug-01, Volume: 32, Issue:31, 2012
Effects of group II metabotropic glutamate receptor modulation on ethanol- and sucrose-seeking and consumption in the rat.Alcohol (Fayetteville, N.Y.), , Volume: 66, 2018
Alcohol consumption increases basal extracellular glutamate in the nucleus accumbens core of Sprague-Dawley rats without increasing spontaneous glutamate release.The European journal of neuroscience, , Volume: 44, Issue:2, 2016
Activation of mGluR2/3 following stress hormone exposure restores sensitivity to alcohol in rats.Alcohol (Fayetteville, N.Y.), , Volume: 49, Issue:6, 2015
Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:3, 2014
Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intake.Biological psychiatry, , May-01, Volume: 67, Issue:9, 2010
Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Sep-27, Volume: 26, Issue:39, 2006
Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG.European journal of pharmacology, , Dec-28, Volume: 528, Issue:1-3, 2005
Reversal of alcohol dependence-induced deficits in cue-guided behavior via mGluR2/3 signaling in mice.Psychopharmacology, , Volume: 233, Issue:2, 2016
Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:3, 2014
Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR 2/3 agonist LY379268 and increased functional activity of mGluR 2/3 in rats with a history of ethanol dependence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 36, Issue:13, 2011
Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of ethanol dependence.Biological psychiatry, , May-01, Volume: 67, Issue:9, 2010
Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Sep-27, Volume: 26, Issue:39, 2006
Group II Metabotropic Glutamate Receptors Reduce Apoptosis and Regulate BDNF and GDNF Levels in Hypoxic-Ischemic Injury in Neonatal Rats.International journal of molecular sciences, , Jun-23, Volume: 23, Issue:13, 2022
Pharmacological activation of mGlu2/3 metabotropic glutamate receptors protects retinal neurons against anoxic damage in the goldfish Carassius auratus.Experimental eye research, , Volume: 84, Issue:3, 2007
Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist.Neuroreport, , Dec-16, Volume: 10, Issue:18, 1999
S-SCAM, a rare copy number variation gene, induces schizophrenia-related endophenotypes in transgenic mouse model.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Feb-04, Volume: 35, Issue:5, 2015
The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety.European journal of pharmacology, , Sep-05, Volume: 715, Issue:1-3, 2013
Alcohol-induced neurodegeneration, suppression of transforming growth factor-beta, and cognitive impairment in rats: prevention by group II metabotropic glutamate receptor activation.Biological psychiatry, , May-01, Volume: 67, Issue:9, 2010
The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268.CNS drug reviews, ,Winter, Volume: 13, Issue:4, 2007
Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Sep-27, Volume: 26, Issue:39, 2006
Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.Journal of neurotrauma, , Volume: 20, Issue:4, 2003
Group II Metabotropic Glutamate Receptors Reduce Apoptosis and Regulate BDNF and GDNF Levels in Hypoxic-Ischemic Injury in Neonatal Rats.International journal of molecular sciences, , Jun-23, Volume: 23, Issue:13, 2022
Neuroprotective effects of selective group II mGluR activation in brain trauma and traumatic neuronal injury.Journal of neurotrauma, , Volume: 23, Issue:2, 2006
Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.Journal of neurotrauma, , Volume: 20, Issue:4, 2003
Pharmacology and neuroprotective actions of mGlu receptor ligands.Developmental medicine and child neurology. Supplement, , Volume: 86, 2001
Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo.The Journal of pharmacology and experimental therapeutics, , Volume: 294, Issue:3, 2000
LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia.Neuroscience letters, , Oct-08, Volume: 273, Issue:3, 1999
Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist.Neuroreport, , Dec-16, Volume: 10, Issue:18, 1999
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.Pharmacology, biochemistry, and behavior, , Volume: 73, Issue:2, 2002
Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 361, Issue:1, 2000
(Proceedings of the National Academy of Sciences of the United States of America, , 03-26, Volume: 116, Issue:13, 2019
On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.Neuropharmacology, , Volume: 62, Issue:1, 2012
mGlu3 receptor blockade inhibits proliferation and promotes astrocytic phenotype in glioma stem cells.Cell biology international, , Volume: 38, Issue:4, 2014
Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells.Neuropharmacology, , Volume: 55, Issue:4, 2008
Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells.Journal of neurochemistry, , Volume: 84, Issue:6, 2003
Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:10, 2006
The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking.Neuroreport, , Jun-21, Volume: 16, Issue:9, 2005
A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Nov-24, Volume: 24, Issue:47, 2004
Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.Neuroscience letters, , 10-15, Volume: 763, 2021
Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.The Journal of pharmacology and experimental therapeutics, , Volume: 379, Issue:1, 2021
BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.Brain research, , Sep-14, Volume: 1473, 2012
The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.Neurobiology of disease, , Volume: 47, Issue:1, 2012
Early defect of transforming growth factor β1 formation in Huntington's disease.Journal of cellular and molecular medicine, , Volume: 15, Issue:3, 2011
The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.Brain research, , Sep-03, Volume: 1019, Issue:1-2, 2004
mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists.Molecular pain, , Jan-14, Volume: 7, 2011
Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.Molecular pharmacology, , Volume: 75, Issue:5, 2009
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.Neuropharmacology, , Volume: 49 Suppl 1, 2005
Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo.British journal of pharmacology, , Volume: 135, Issue:5, 2002
The mGluRJournal of psychopharmacology (Oxford, England), , Volume: 33, Issue:12, 2019
The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.Neuropharmacology, , Volume: 85, 2014
Impaired fear memory specificity associated with deficient endocannabinoid-dependent long-term plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:7, 2014
Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats.Journal of pharmacological sciences, , Volume: 122, Issue:1, 2013
Amygdala group II mGluRs mediate the inhibitory effects of systemic group II mGluR activation on behavior and spinal neurons in a rat model of arthritis pain.Neuropharmacology, , 11-01, Volume: 158, 2019
Group II mGluRs modulate baseline and arthritis pain-related synaptic transmission in the rat medial prefrontal cortex.Neuropharmacology, , Volume: 95, 2015
mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists.Molecular pain, , Jan-14, Volume: 7, 2011
Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.Molecular pharmacology, , Volume: 75, Issue:5, 2009
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.Neuropharmacology, , Volume: 49 Suppl 1, 2005
Antioxidant and neuroprotective effects of mGlu3 receptor activation on astrocytes aged in vitro.Neurochemistry international, , Volume: 140, 2020
Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.Neuropharmacology, , 07-15, Volume: 137, 2018
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.Neuropharmacology, , Volume: 86, 2014
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:4, 2012
Nicotine exposure during adolescence leads to short- and long-term changes in spike timing-dependent plasticity in rat prefrontal cortex.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Aug-01, Volume: 32, Issue:31, 2012
The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis.Pharmacology, biochemistry, and behavior, , Volume: 122, 2014
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.Neuron, , Apr-10, Volume: 78, Issue:1, 2013
Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 anMolecular pharmacology, , Volume: 79, Issue:3, 2011
The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis.Neuropharmacology, , Volume: 47, Issue:8, 2004
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.Translational psychiatry, , 10-09, Volume: 8, Issue:1, 2018
Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.Neuropharmacology, , 07-15, Volume: 137, 2018
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.Translational psychiatry, , Apr-19, Volume: 6, 2016
mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Psychopharmacology, , Volume: 233, Issue:8, 2016
S-SCAM, a rare copy number variation gene, induces schizophrenia-related endophenotypes in transgenic mouse model.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Feb-04, Volume: 35, Issue:5, 2015
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.Neuropharmacology, , Volume: 86, 2014
The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.Behavioural brain research, , Nov-01, Volume: 256, 2013
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:4, 2012
The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.Psychopharmacology, , Volume: 214, Issue:1, 2011
Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.European journal of pharmacology, , Aug-10, Volume: 639, Issue:1-3, 2010
Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:6, 2009
Glutamate agonists for schizophrenia stimulate dopamine D2High receptors.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia.Synapse (New York, N.Y.), , Volume: 62, Issue:11, 2008
A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.The Journal of pharmacology and experimental therapeutics, , Volume: 315, Issue:3, 2005
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:9, 2003
Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats.Pharmacology, biochemistry, and behavior, , Volume: 73, Issue:2, 2002
In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands.Journal of neurochemistry, , Volume: 88, Issue:5, 2004
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists fJournal of medicinal chemistry, , Mar-25, Volume: 42, Issue:6, 1999
Downregulation of mGluR2/3 receptors during morphine withdrawal in rats impairs mGluR2/3- and NMDA receptor-dependent long-term depression in the nucleus accumbens.Neuroscience letters, , 01-18, Volume: 690, 2019
Potentiation of synaptic strength and intrinsic excitability in the nucleus accumbens after 10 days of morphine withdrawal.Journal of neuroscience research, , Volume: 90, Issue:6, 2012
Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:8, 2008
Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats.Biochemical pharmacology, , Oct-15, Volume: 74, Issue:8, 2007
Endogenous glutamate within the prelimbic and infralimbic cortices regulates the incubation of cocaine-seeking in rats.Neuropharmacology, , Volume: 128, 2018
Intermittent intake of rapid cocaine injections promotes robust psychomotor sensitization, increased incentive motivation for the drug and mGlu2/3 receptor dysregulation.Neuropharmacology, , 05-01, Volume: 117, 2017
Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys.Psychopharmacology, , Volume: 233, Issue:10, 2016
The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.Drug and alcohol dependence, , Sep-01, Volume: 166, 2016
Regulation of cocaine-induced reinstatement by group II metabotropic glutamate receptors in the ventral tegmental area.Psychopharmacology, , Volume: 220, Issue:1, 2012
(-)-2-oxa-4-aminobicylco[3.1.0]hexane-4,6-dicarboxylic acid (LY379268) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine (MTEP) similarly attenuate stress-induced reinstatement of cocaine seeking.Addiction biology, , Volume: 17, Issue:3, 2012
Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism.Journal of neurochemistry, , Volume: 112, Issue:2, 2010
Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence.Biological psychiatry, , Aug-01, Volume: 68, Issue:3, 2010
Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:8, 2008
Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving.Biological psychiatry, , Mar-01, Volume: 61, Issue:5, 2007
The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats.Psychopharmacology, , Volume: 186, Issue:2, 2006
Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys.The Journal of pharmacology and experimental therapeutics, , Volume: 318, Issue:2, 2006
Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer.The Journal of neuroscience : the official journal of the Society for Neuroscience, , May-19, Volume: 24, Issue:20, 2004
The mGluRJournal of psychopharmacology (Oxford, England), , Volume: 33, Issue:12, 2019
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.Translational psychiatry, , 10-09, Volume: 8, Issue:1, 2018
Endogenous glutamate within the prelimbic and infralimbic cortices regulates the incubation of cocaine-seeking in rats.Neuropharmacology, , Volume: 128, 2018
Intermittent intake of rapid cocaine injections promotes robust psychomotor sensitization, increased incentive motivation for the drug and mGlu2/3 receptor dysregulation.Neuropharmacology, , 05-01, Volume: 117, 2017
The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.Drug and alcohol dependence, , Sep-01, Volume: 166, 2016
Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys.Psychopharmacology, , Volume: 233, Issue:10, 2016
Regulation of cocaine-induced reinstatement by group II metabotropic glutamate receptors in the ventral tegmental area.Psychopharmacology, , Volume: 220, Issue:1, 2012
(-)-2-oxa-4-aminobicylco[3.1.0]hexane-4,6-dicarboxylic acid (LY379268) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine (MTEP) similarly attenuate stress-induced reinstatement of cocaine seeking.Addiction biology, , Volume: 17, Issue:3, 2012
Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism.Journal of neurochemistry, , Volume: 112, Issue:2, 2010
Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence.Biological psychiatry, , Aug-01, Volume: 68, Issue:3, 2010
Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:8, 2008
Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving.Biological psychiatry, , Mar-01, Volume: 61, Issue:5, 2007
The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats.Psychopharmacology, , Volume: 186, Issue:2, 2006
Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys.The Journal of pharmacology and experimental therapeutics, , Volume: 318, Issue:2, 2006
Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer.The Journal of neuroscience : the official journal of the Society for Neuroscience, , May-19, Volume: 24, Issue:20, 2004
The mGluRJournal of psychopharmacology (Oxford, England), , Volume: 33, Issue:12, 2019
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.Translational psychiatry, , 10-09, Volume: 8, Issue:1, 2018
Reversal of alcohol dependence-induced deficits in cue-guided behavior via mGluR2/3 signaling in mice.Psychopharmacology, , Volume: 233, Issue:2, 2016
Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:3, 2014
Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR 2/3 agonist LY379268 and increased functional activity of mGluR 2/3 in rats with a history of ethanol dependence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 36, Issue:13, 2011
Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of ethanol dependence.Biological psychiatry, , May-01, Volume: 67, Issue:9, 2010
Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Sep-27, Volume: 26, Issue:39, 2006
Group II Metabotropic Glutamate Receptors Reduce Apoptosis and Regulate BDNF and GDNF Levels in Hypoxic-Ischemic Injury in Neonatal Rats.International journal of molecular sciences, , Jun-23, Volume: 23, Issue:13, 2022
Pharmacological activation of mGlu2/3 metabotropic glutamate receptors protects retinal neurons against anoxic damage in the goldfish Carassius auratus.Experimental eye research, , Volume: 84, Issue:3, 2007
Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist.Neuroreport, , Dec-16, Volume: 10, Issue:18, 1999
Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.Journal of neurotrauma, , Volume: 20, Issue:4, 2003
Group II Metabotropic Glutamate Receptors Reduce Apoptosis and Regulate BDNF and GDNF Levels in Hypoxic-Ischemic Injury in Neonatal Rats.International journal of molecular sciences, , Jun-23, Volume: 23, Issue:13, 2022
Neuroprotective effects of selective group II mGluR activation in brain trauma and traumatic neuronal injury.Journal of neurotrauma, , Volume: 23, Issue:2, 2006
Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.Journal of neurotrauma, , Volume: 20, Issue:4, 2003
Pharmacology and neuroprotective actions of mGlu receptor ligands.Developmental medicine and child neurology. Supplement, , Volume: 86, 2001
Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo.The Journal of pharmacology and experimental therapeutics, , Volume: 294, Issue:3, 2000
Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist.Neuroreport, , Dec-16, Volume: 10, Issue:18, 1999
LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia.Neuroscience letters, , Oct-08, Volume: 273, Issue:3, 1999
Alcohol-induced neurodegeneration, suppression of transforming growth factor-beta, and cognitive impairment in rats: prevention by group II metabotropic glutamate receptor activation.Biological psychiatry, , May-01, Volume: 67, Issue:9, 2010
Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:6, 2009
Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.Neuroscience letters, , 10-15, Volume: 763, 2021
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
(Proceedings of the National Academy of Sciences of the United States of America, , 03-26, Volume: 116, Issue:13, 2019
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.Translational psychiatry, , 10-09, Volume: 8, Issue:1, 2018
Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.Neuropharmacology, , 07-15, Volume: 137, 2018
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.Translational psychiatry, , Apr-19, Volume: 6, 2016
mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Psychopharmacology, , Volume: 233, Issue:8, 2016
Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.Neurobiology of disease, , Volume: 74, 2015
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.Neuropharmacology, , Volume: 86, 2014
The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis.Pharmacology, biochemistry, and behavior, , Volume: 122, 2014
Impaired fear memory specificity associated with deficient endocannabinoid-dependent long-term plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:7, 2014
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.Neuron, , Apr-10, Volume: 78, Issue:1, 2013
Prefrontal synaptic markers of cocaine addiction-like behavior in rats.Molecular psychiatry, , Volume: 18, Issue:6, 2013
The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.Neurobiology of disease, , Volume: 47, Issue:1, 2012
Potentiation of synaptic strength and intrinsic excitability in the nucleus accumbens after 10 days of morphine withdrawal.Journal of neuroscience research, , Volume: 90, Issue:6, 2012
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:4, 2012
On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.Neuropharmacology, , Volume: 62, Issue:1, 2012
BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.Brain research, , Sep-14, Volume: 1473, 2012
The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.Psychopharmacology, , Volume: 214, Issue:1, 2011
More is less: a disinhibited prefrontal cortex impairs cognitive flexibility.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Dec-15, Volume: 30, Issue:50, 2010
Interhemispheric regulation of the medial prefrontal cortical glutamate stress response in rats.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Jun-02, Volume: 30, Issue:22, 2010
Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of ethanol dependence.Biological psychiatry, , May-01, Volume: 67, Issue:9, 2010
Glial inhibitors influence the mRNA and protein levels of mGlu2/3, 5 and 7 receptors and potentiate the analgesic effects of their ligands in a mouse model of neuropathic pain.Pain, , Dec-15, Volume: 147, Issue:1-3, 2009
Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:6, 2009
Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells.Neuropharmacology, , Volume: 55, Issue:4, 2008
Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats.Neuropharmacology, , Volume: 55, Issue:4, 2008
Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain.Pain, , Sep-30, Volume: 139, Issue:1, 2008
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.Psychopharmacology, , Volume: 196, Issue:3, 2008
Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?Molecular psychiatry, , Volume: 12, Issue:8, 2007
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.Neuropharmacology, , Volume: 49 Suppl 1, 2005
The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.Brain research, , Sep-03, Volume: 1019, Issue:1-2, 2004
In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands.Journal of neurochemistry, , Volume: 88, Issue:5, 2004
Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.Journal of neurotrauma, , Volume: 20, Issue:4, 2003
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:9, 2003
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.Pharmacology, biochemistry, and behavior, , Volume: 73, Issue:2, 2002
Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 361, Issue:1, 2000
(Proceedings of the National Academy of Sciences of the United States of America, , 03-26, Volume: 116, Issue:13, 2019
On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.Neuropharmacology, , Volume: 62, Issue:1, 2012
mGlu3 receptor blockade inhibits proliferation and promotes astrocytic phenotype in glioma stem cells.Cell biology international, , Volume: 38, Issue:4, 2014
Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells.Neuropharmacology, , Volume: 55, Issue:4, 2008
Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells.Journal of neurochemistry, , Volume: 84, Issue:6, 2003
Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:10, 2006
The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking.Neuroreport, , Jun-21, Volume: 16, Issue:9, 2005
A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Nov-24, Volume: 24, Issue:47, 2004
Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.Neuroscience letters, , 10-15, Volume: 763, 2021
Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.The Journal of pharmacology and experimental therapeutics, , Volume: 379, Issue:1, 2021
BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.Brain research, , Sep-14, Volume: 1473, 2012
The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.Neurobiology of disease, , Volume: 47, Issue:1, 2012
Early defect of transforming growth factor β1 formation in Huntington's disease.Journal of cellular and molecular medicine, , Volume: 15, Issue:3, 2011
The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.Brain research, , Sep-03, Volume: 1019, Issue:1-2, 2004
Glial inhibitors influence the mRNA and protein levels of mGlu2/3, 5 and 7 receptors and potentiate the analgesic effects of their ligands in a mouse model of neuropathic pain.Pain, , Dec-15, Volume: 147, Issue:1-3, 2009
Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain.Pain, , Sep-30, Volume: 139, Issue:1, 2008
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.Neuropharmacology, , Volume: 49 Suppl 1, 2005
Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo.British journal of pharmacology, , Volume: 135, Issue:5, 2002
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.Translational psychiatry, , 10-09, Volume: 8, Issue:1, 2018
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.Psychopharmacology, , Volume: 196, Issue:3, 2008
Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist.Biological psychiatry, , Nov-01, Volume: 64, Issue:9, 2008
Blockade of group II metabotropic glutamate receptors in the nucleus accumbens produces hyperlocomotion in rats previously exposed to amphetamine.Neuropharmacology, , Volume: 51, Issue:5, 2006
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:9, 2003
mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists.Molecular pain, , Jan-14, Volume: 7, 2011
Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.Molecular pharmacology, , Volume: 75, Issue:5, 2009
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.Neuropharmacology, , Volume: 49 Suppl 1, 2005
Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo.British journal of pharmacology, , Volume: 135, Issue:5, 2002
The mGluRJournal of psychopharmacology (Oxford, England), , Volume: 33, Issue:12, 2019
The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.Neuropharmacology, , Volume: 85, 2014
Impaired fear memory specificity associated with deficient endocannabinoid-dependent long-term plasticity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:7, 2014
Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats.Journal of pharmacological sciences, , Volume: 122, Issue:1, 2013
Alcohol-induced neurodegeneration, suppression of transforming growth factor-beta, and cognitive impairment in rats: prevention by group II metabotropic glutamate receptor activation.Biological psychiatry, , May-01, Volume: 67, Issue:9, 2010
Pharmacology and neuroprotective actions of mGlu receptor ligands.Developmental medicine and child neurology. Supplement, , Volume: 86, 2001
Amygdala group II mGluRs mediate the inhibitory effects of systemic group II mGluR activation on behavior and spinal neurons in a rat model of arthritis pain.Neuropharmacology, , 11-01, Volume: 158, 2019
Group II mGluRs modulate baseline and arthritis pain-related synaptic transmission in the rat medial prefrontal cortex.Neuropharmacology, , Volume: 95, 2015
mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonists.Molecular pain, , Jan-14, Volume: 7, 2011
Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.Molecular pharmacology, , Volume: 75, Issue:5, 2009
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.Neuropharmacology, , Volume: 49 Suppl 1, 2005
Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.Neuropharmacology, , 07-15, Volume: 137, 2018
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.Neuropharmacology, , Volume: 86, 2014
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:4, 2012
The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis.Pharmacology, biochemistry, and behavior, , Volume: 122, 2014
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.Neuron, , Apr-10, Volume: 78, Issue:1, 2013
Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 anMolecular pharmacology, , Volume: 79, Issue:3, 2011
The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis.Neuropharmacology, , Volume: 47, Issue:8, 2004
A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity.Pharmacology, biochemistry, and behavior, , Volume: 183, 2019
Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys.Psychopharmacology, , Volume: 233, Issue:10, 2016
Regulation of cocaine-induced reinstatement by group II metabotropic glutamate receptors in the ventral tegmental area.Psychopharmacology, , Volume: 220, Issue:1, 2012
A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Nov-24, Volume: 24, Issue:47, 2004
Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.Neuropharmacology, , 07-15, Volume: 137, 2018
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.Translational psychiatry, , 10-09, Volume: 8, Issue:1, 2018
mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Psychopharmacology, , Volume: 233, Issue:8, 2016
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.Translational psychiatry, , Apr-19, Volume: 6, 2016
S-SCAM, a rare copy number variation gene, induces schizophrenia-related endophenotypes in transgenic mouse model.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Feb-04, Volume: 35, Issue:5, 2015
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.Neuropharmacology, , Volume: 86, 2014
The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.Behavioural brain research, , Nov-01, Volume: 256, 2013
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:4, 2012
The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.Psychopharmacology, , Volume: 214, Issue:1, 2011
Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.European journal of pharmacology, , Aug-10, Volume: 639, Issue:1-3, 2010
Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:6, 2009
Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia.Synapse (New York, N.Y.), , Volume: 62, Issue:11, 2008
Glutamate agonists for schizophrenia stimulate dopamine D2High receptors.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.The Journal of pharmacology and experimental therapeutics, , Volume: 315, Issue:3, 2005
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:9, 2003
Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats.Pharmacology, biochemistry, and behavior, , Volume: 73, Issue:2, 2002
In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands.Journal of neurochemistry, , Volume: 88, Issue:5, 2004
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists fJournal of medicinal chemistry, , Mar-25, Volume: 42, Issue:6, 1999
Downregulation of mGluR2/3 receptors during morphine withdrawal in rats impairs mGluR2/3- and NMDA receptor-dependent long-term depression in the nucleus accumbens.Neuroscience letters, , 01-18, Volume: 690, 2019
Potentiation of synaptic strength and intrinsic excitability in the nucleus accumbens after 10 days of morphine withdrawal.Journal of neuroscience research, , Volume: 90, Issue:6, 2012
Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during abstinence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:8, 2008
Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats.Biochemical pharmacology, , Oct-15, Volume: 74, Issue:8, 2007
Safety/Toxicity (2)
Long-term Use (3)
| Article | Year |
|---|
Stimulation of the metabotropic glutamate (mGlu) 2 receptor attenuates the MK-801-induced increase in the immobility time in the forced swimming test in rats.
Pharmacological reports : PR, , Volume: 68, Issue:1 | 2016 |
Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.
Psychopharmacology, , Volume: 217, Issue:1 | 2011 |
Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain.
Pain, , Sep-30, Volume: 139, Issue:1 | 2008 |
Pharmacokinetics (1)
Bioavailability (2)
| Article | Year |
|---|
Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
Journal of medicinal chemistry, , Jan-25, Volume: 50, Issue:2 | 2007 |
Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Neuropharmacology, , Volume: 45, Issue:2 | 2003 |
Dosage (9)
| Article | Year |
|---|
Exogenous BDNF facilitates strategy set-shifting by modulating glutamate dynamics in the dorsal striatum.
Neuropharmacology, , Volume: 75 | 2013 |
Effects of microinjections of Group II metabotropic glutamate agents into the amygdala on sleep.
Brain research, , May-03, Volume: 1452 | 2012 |
Regulation of cocaine-induced reinstatement by group II metabotropic glutamate receptors in the ventral tegmental area.
Psychopharmacology, , Volume: 220, Issue:1 | 2012 |
(-)-2-oxa-4-aminobicylco[3.1.0]hexane-4,6-dicarboxylic acid (LY379268) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine (MTEP) similarly attenuate stress-induced reinstatement of cocaine seeking.
Addiction biology, , Volume: 17, Issue:3 | 2012 |
Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin.
Experimental neurology, , Volume: 215, Issue:2 | 2009 |
Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:9 | 2008 |
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.
Neuropharmacology, , Volume: 49 Suppl 1 | 2005 |
Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels.
Neuropharmacology, , Volume: 48, Issue:7 | 2005 |
Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268.
Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 361, Issue:1 | 2000 |